Subtopic Deep Dive
Survival Prediction in Pulmonary Hypertension
Research Guide
What is Survival Prediction in Pulmonary Hypertension?
Survival prediction in pulmonary hypertension uses multiparametric risk scores incorporating 6MWD, NT-proBNP, hemodynamics, and echo indices to estimate patient prognosis.
Registry analyses from REVEAL and French PAH cohorts refine tools like REVEAL 2.0 for treatment decisions (Benza et al., 2010). ESC/ERS guidelines integrate these scores for risk stratification (Galiè et al., 2015; 6860 citations). Over 10 key papers establish BNP and hemodynamics as core predictors (Nagaya et al., 2000; 877 citations).
Why It Matters
Accurate survival prediction guides therapy escalation in pulmonary arterial hypertension (PAH), identifying high-risk patients for lung transplantation or aggressive treatments (Benza et al., 2010). REVEAL score from 2716 patients predicts 1-year survival, informing clinical trials and resource allocation (Benza et al., 2010). ESC/ERS guidelines apply risk scores to adjust therapies like endothelin antagonists, improving outcomes in prevalent cohorts (Galiè et al., 2015; Humbert et al., 2010). BNP levels independently predict mortality in primary PH, enabling early intervention (Nagaya et al., 2000).
Key Research Challenges
Refining Risk Score Accuracy
REVEAL score from 2716 PAH patients achieves good calibration but needs updates for new therapies (Benza et al., 2010). Incident vs. prevalent cohort survival differs, complicating predictions (Humbert et al., 2010). Echo and hemodynamic integration remains inconsistent across registries.
Biomarker Validation Across PH Groups
Plasma BNP prognosticates in primary PH but validation in Groups 2-5 PH is limited (Nagaya et al., 2000). ESC/ERS guidelines note variability in NT-proBNP cutoffs (Galiè et al., 2015). Functional measures like 6MWD require standardization.
Long-term Prediction Modeling
Current scores focus on 1-year survival, lacking models for 5-year outcomes (Benza et al., 2010). Registry data show survival improvements, but tools lag behind (Humbert et al., 2010). Incorporating right heart failure metrics adds complexity (Konstam et al., 2018).
Essential Papers
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galiè, Marc Humbert, Jean-Luc Vachiéry et al. · 2015 · European Heart Journal · 6.9K citations
Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanor...
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert et al. · 2009 · European Heart Journal · 3.8K citations
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the Eu...
Predicting Survival in Pulmonary Arterial Hypertension
Raymond L. Benza, Dave P. Miller, Mardi Gomberg‐Maitland et al. · 2010 · Circulation · 1.5K citations
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clin...
Guidelines for the diagnosis and treatment of pulmonary hypertension
Marius M. Hoeper, Marc Humbert, Adam Torbicki et al. · 2009 · European Respiratory Journal · 1.3K citations
Task force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society endorsed by the International Society of Heart and Lu...
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
Noritoshi Nagaya, Toshio Nishikimi, Masaaki Uematsu et al. · 2000 · Circulation · 877 citations
Background —Plasma brain natriuretic peptide (BNP) level increases in proportion to the degree of right ventricular dysfunction in pulmonary hypertension. We sought to assess the prognostic signifi...
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
Marvin A. Konstam, Michael S. Kiernan, Daniel Bernstein et al. · 2018 · Circulation · 844 citations
Background and Purpose: The diverse causes of right-sided heart failure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, vo...
Risk stratification and medical therapy of pulmonary arterial hypertension
Nazzareno Galiè, Richard N. Channick, Robert P. Frantz et al. · 2018 · European Respiratory Journal · 813 citations
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostac...
Reading Guide
Foundational Papers
Start with Benza et al. (2010) for REVEAL score derivation from 2716 patients; Galiè et al. (2009; 3842 citations) for initial ESC/ERS framework; Nagaya et al. (2000) for BNP prognostic role.
Recent Advances
Galiè et al. (2015; 6860 citations) updates guidelines with risk tools; Humbert et al. (2010) analyzes incident/prevalent survival; Konstam et al. (2018) covers right heart failure metrics.
Core Methods
REVEAL multiparametric scoring (Benza et al., 2010); BNP/NT-proBNP thresholding (Nagaya et al., 2000); hemodynamic/6MWD risk stratification per ESC/ERS (Galiè et al., 2015).
How PapersFlow Helps You Research Survival Prediction in Pulmonary Hypertension
Discover & Search
Research Agent uses searchPapers and citationGraph on 'REVEAL 2.0' to map 1530-citation Benza et al. (2010) network, revealing Humbert et al. (2010) French registry links; exaSearch finds recent validations, findSimilarPapers expands to ESC/ERS guidelines (Galiè et al., 2015).
Analyze & Verify
Analysis Agent applies readPaperContent to extract REVEAL variables from Benza et al. (2010), verifies survival equations via runPythonAnalysis (pandas for cohort stats, matplotlib ROC curves), and uses verifyResponse (CoVe) with GRADE grading to confirm BNP cutoffs from Nagaya et al. (2000) against guidelines.
Synthesize & Write
Synthesis Agent detects gaps in long-term predictions post-REVEAL (Benza et al., 2010), flags contradictions between incident/prevalent survival (Humbert et al., 2010); Writing Agent uses latexEditText for risk score tables, latexSyncCitations for 10+ papers, latexCompile for reports, exportMermaid for cohort flowcharts.
Use Cases
"Reproduce REVEAL survival calculator from Benza 2010 with Python."
Research Agent → searchPapers('REVEAL Benza') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas loads 2716-patient data, computes 1-year risk) → matplotlib survival plot output.
"Draft LaTeX review on PH risk scores citing Galiè 2015 and Nagaya 2000."
Synthesis Agent → gap detection (post-2015 updates) → Writing Agent → latexEditText (adds sections), latexSyncCitations (10 ESC/ERS refs), latexCompile → PDF with risk stratification table.
"Find code for BNP threshold analysis in PH survival prediction."
Research Agent → paperExtractUrls(Nagaya 2000) → Code Discovery → paperFindGithubRepo → githubRepoInspect → extracts R script for BNP Kaplan-Meier curves.
Automated Workflows
Deep Research workflow scans 50+ PH papers via searchPapers, structures REVEAL vs. French registry comparison report with GRADE scores. DeepScan's 7-steps verify BNP prognostic claims (Nagaya et al., 2000) via CoVe checkpoints and Python stats. Theorizer generates hypotheses on echo-hemodynamic integration from Galiè guidelines (2015).
Frequently Asked Questions
What defines survival prediction in pulmonary hypertension?
Multiparametric risk scores use 6MWD, NT-proBNP, hemodynamics, and echo indices to estimate prognosis (Benza et al., 2010; Galiè et al., 2015).
What are core methods for PH survival prediction?
REVEAL score from 2716 PAH patients integrates 12 variables for 1-year survival (Benza et al., 2010). BNP levels predict mortality independently (Nagaya et al., 2000). ESC/ERS guidelines recommend multiparameter assessment.
What are key papers on PH survival prediction?
Benza et al. (2010; 1530 citations) introduced REVEAL; Nagaya et al. (2000; 877 citations) validated BNP; Galiè et al. (2015; 6860 citations) integrated into guidelines.
What open problems exist in PH survival prediction?
Long-term (>1-year) models lag behind therapy advances; validation across PH groups 2-5 needed; standardization of functional tests like 6MWD unresolved (Humbert et al., 2010).
Research Pulmonary Hypertension Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Survival Prediction in Pulmonary Hypertension with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers